| Website | probiodrug.de |
| Category | BioTech |
| Phone | +49 345 5559900 |
| info@probiodrug.de | |
| Employees | |
| Founded | 1997 |
| TOTAL | $73.4M |
| VENTURE FUNDING TOTAL | $73.4M |
| Series B, 11/09 BB Biotech Ventures Edmond de Rothschild Venture Capital Biogen Idec New Ventures IBG Fonds TVM Capital HBM BioVentures CFH Life Sciences Partners | $54M |
| Venture Round, 1/12 BB Biotech Ventures Edmond de Rothschild Investment Partners Life Sciences Partners Biogen Idec New Ventures TVM Capital HBM BioVentures | €15M |
Probiodrug is a privately held biopharmaceutical company focused on the development of innovative small molecule drugs. The Company was founded in 1997 and has raised a total of $52 million in private equity. In addition, it has generated more than $50 million in revenues and is debt-free. Probiodrug is pioneering an industrialized approach for making innovative targets pharmacologically accessible. Its core competence is the elucidation of the structure, biochemistry, and biology as well as the pathophysiology of regulatory peptides and enzymes modifying the activity of specific proteins and pathways. Based on this expertise, the Company is developing inhibitors and ligands targeting key enzymes such as proteases and kinases. The most promising compounds are then developed by Probiodrug as drug candidates for the treatment of major diseases such as Alzheimer’s disease or chronic inflammatory disorders.
Probiodrug addresses major pharmaceutical markets such as Alzheimer’s disease, psoriasis, rheumatoid arthritis or cardiovascular diseases.
